Ciplacef

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ciplacef

Quick Facts: Ciplacef

Property Description
Active ingredient (INN) Ceftriaxone (often as sodium salt)
Form Sterile powder for solution for injection or infusion
Pharmacological class Third-Generation Cephalosporin Antibiotic
Common use Resolution of severe bacterial infections (Prescription-only)
Origin Semi-synthetic compound

What Type of Antibiotic is Ciplacef?

Ciplacef is a prescription-only medicine manufactured by Cipla Ltd. that belongs to the third-generation cephalosporin class of antibiotics. Its active component is Ceftriaxone. Ceftriaxone is a semi-synthetic derivative of the beta-lactam family, distinguished by its broad-spectrum activity, which is clinically recognized for its effectiveness against a wide range of bacteria. This positioning is particularly important because third-generation cephalosporins, unlike earlier generations, show enhanced stability against certain bacterial resistance enzymes. This characteristic allows Ceftriaxone to be reliably used in complicated or severe infections where resistance is a significant concern.


Form, Composition, and General Therapeutic Purpose

The Ciplacef product is typically supplied as a sterile powder for solution, meaning it must be mixed with a diluent before administration. This presentation necessitates the parenteral route (injection or infusion). Its composition relies on the potent, single-active ingredient, Ceftriaxone, though a specific combination product, Ciplacef-S, is also available, which adds Sulbactam (a beta-lactamase inhibitor) to enhance the drug's power against resistant strains. The drug's central purpose is to achieve a swift, definitive resolution of severe bacterial infections. The bactericidal action of Ceftriaxone actively kills pathogens by interfering with their cell wall construction, ensuring it remains an essential tool in treating serious infections that require high drug concentrations in the bloodstream and tissues.

Regulatory References

  1. NIH Cephalosporins Review
  2. MedlinePlus Ceftriaxone

What side effects are possible with Ciplacef?

Possible Side Effects and Safety Information: Ciplacef

Ciplacef (Cefazolin) is an antibiotic used to treat various bacterial infections. Like all medicines, it can cause side effects, although not everyone experiences them. Most side effects are mild and temporary.

Common Side Effects

The most frequently reported side effects are generally mild and may include:

  • Gastrointestinal issues: Diarrhea, nausea, vomiting, or stomach discomfort.
  • Local reactions: Pain, swelling, or redness at the injection site (when administered intravenously or intramuscularly).

Less Common, More Serious Side Effects

While rare, some side effects require immediate medical attention. If you experience any signs of a severe allergic reaction (anaphylaxis), such as a rash, itching, severe dizziness, trouble breathing, or swelling of the face, tongue, or throat, seek emergency care immediately.

Other serious, though infrequent, side effects can include:

  • Severe diarrhea (possibly due to Clostridium difficile infection).
  • Liver or kidney problems, which may be indicated by yellowing of the skin or eyes (jaundice) or changes in the amount of urine.
  • Blood disorders, such as a decrease in white blood cells or platelets, which can increase the risk of infection or bleeding.

Safety Information and Precautions

It is important to inform your healthcare provider about any pre-existing conditions, especially kidney disease or a history of gastrointestinal problems, such as colitis. Also, disclose all current medications, including over-the-counter drugs and herbal supplements, to check for potential drug interactions.

Ciplacef is generally contraindicated in patients with a known hypersensitivity or severe allergic reaction to Cefazolin or other cephalosporin antibiotics.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Ciplacef (Ceftriaxone) documents specific clinical manifestations and requires immediate emergency actions if overexposure is suspected.


Documented Overdose Manifestations

Overdose presentations may involve Central Nervous System (CNS) effects, including documented seizures, convulsions, or encephalopathy (e.g., altered mental state). High-dose exposure has also been associated with biliary pseudolithiasis (sludge), which may present with pain, nausea, and vomiting.

Serious outcomes documented include post-renal acute renal failure secondary to urolithiasis risk, and the severe complication of ceftriaxone-calcium precipitation, particularly if the medicine is mixed with calcium-containing intravenous solutions.


Emergency Actions and Management

Regulatory guidance mandates that patients seek immediate medical attention for all suspected overdose scenarios. Urgent contact with emergency services or a Poison Control center is required if severe symptoms occur, such as collapse or a seizure.

Overdose management is limited to symptomatic and supportive treatment. Official labeling confirms that no specific antidote is known, and hemodialysis is not effective at reducing Ceftriaxone levels. Specific considerations apply to neonates (precipitation risk) and elderly patients with severe renal impairment (encephalopathy risk).

Therapeutic Uses of Ciplacef

What Ciplacef treats: main uses and benefits

Ciplacef is a medication that may assist with managing bacterial infections across various sites in the body. The medication is applied in addressing conditions presenting with systemic or localized discomfort caused by susceptible pathogens. This medicine may assist with conditions involving episodic or fluctuating manifestations across various physiological systems.

This medication is considered relevant for easing symptoms that interfere with daily comfort in therapeutic domains such as urinary tract infections (UTIs), lower respiratory tract infections, skin and soft tissue infections, bone and joint infections, and intra-abdominal infections. It is commonly used when short-term symptomatic assistance is needed and provides support that helps ease the overall symptom burden during phases when symptoms become more noticeable.

It provides supportive relief when symptoms interfere with routine activities and is applied in clinical settings that involve acute or unstable symptom patterns.

This medication generally helps improve day-to-day comfort during symptomatic periods and contributes to improved comfort during periods of heightened symptoms.


Quick Fact: Supports patients during periods of symptoms related to physical discomfort

Regulatory References

  1. NIH DailyMed FDA-approved Label for Ciprofloxacin

Eligibility and Restrictions for Use

Ciplacef (Ceftriaxone) eligibility is strictly defined by regulatory documents, focusing on absolute exclusions and specific restrictions related to age and organ function.

Contraindications (Must Not Use)

The medicine is contraindicated in the following populations:

  • Patients with known hypersensitivity to ceftriaxone, any of its components, or to any other cephalosporin antibiotic.
  • Premature neonates up to a postmenstrual age of 41 weeks (gestational age + chronological age).
  • Hyperbilirubinemic neonates (due to the risk of bilirubin encephalopathy).
  • Neonates ( le 28 days) who require (or are expected to require) treatment with calcium-containing IV solutions.

Condition-Based Restrictions

Condition/Status Eligibility Classification
Combined hepatic and renal dysfunction Restricted: Maximum daily dosage must not exceed 2 grams.
History of penicillin allergy Conditional: Should be given cautiously due to potential cross-hypersensitivity.
Pregnancy Conditional: Use only if clearly needed (FDA Category B).
Lactation (Breastfeeding) Conditional: Caution should be exercised as the drug is excreted in breast milk.

Use is established and generally permitted in older children, adolescents, adults, and the elderly, provided organ function is satisfactory.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile of Ciplacef (Ceftriaxone) is defined by documented physical incompatibilities and specific pharmacodynamic effects.

A major restriction involves Calcium-Containing Intravenous Solutions. Ciplacef is contraindicated in neonates (le 28 days old) who are receiving or are expected to receive intravenous calcium due to the risk of fatal ceftriaxone-calcium salt precipitation. This prohibition is mandatory even if separate intravenous lines are used.

In all age groups, Ciplacef must not be administered simultaneously with any calcium-containing solution via the same line or Y-site. For patients older than 28 days, sequential administration is permitted only if the infusion line is thoroughly flushed between the two infusions with a compatible fluid.

Pharmacodynamic interactions are documented with Oral Anticoagulants (such as Warfarin), where co-administration may increase the risk of bleeding by causing an alteration in prothrombin time. Furthermore, an additive risk of nephrotoxicity is officially stated when Ciplacef is co-administered with Aminoglycosides. The regulatory documents also list drugs, including Vancomycin, Amsacrine, and Fluconazole, as physically incompatible with Ciplacef, prohibiting their mixture in the same solution.

Mechanism of Action

Direct Inhibition of Bacterial Cell Wall Assembly

Ciplacef's core mechanism centers on its ability to covalently inhibit bacterial Penicillin-Binding Proteins (PBPs)—enzymes essential for forming the strong peptidoglycan cross-links that define the cell wall structure. By halting the final assembly step of this crucial barrier, the drug triggers a cascading failure: the cell wall becomes structurally unsound, leading to the activation of the bacterium’s own autolytic enzymes. The ultimate physiological consequence is the rapid and definitive lysis (bursting) and death of the pathogen, establishing a bactericidal effect.

Mechanistic Protection Against Resistance (Ciplacef-S)

In the combination product Ciplacef-S, the additional component Sulbactam acts to maintain the PBP-inhibitory activity of the core drug. Sulbactam uses irreversible inhibition to neutralize bacterial beta-lactamase enzymes, which are designed to chemically destroy Ceftriaxone. This protection restores the ability of Ceftriaxone to execute its cell wall assembly blockade, thereby restoring Ceftriaxone's PBP inhibition activity against bacterial strains possessing this specific enzymatic defense mechanism.

Dosage and Administration Information

How to Use Ciplacef (Ceftriaxone)

Ciplacef is a prescription medicine administered solely through the parenteral route—either as an intravenous (IV) injection or infusion, or as an intramuscular (IM) injection. It is supplied as a sterile powder and requires reconstitution with an appropriate diluent before administration.

Dosage and Administration Principles

The most common usage pattern involves a standard adult dose of 1 g to 2 g administered once daily (every 24 hours). For the treatment of severe infections, the total daily dose may be increased up to a maximum of 4 g. In cases of co-existing severe renal and hepatic impairment, the daily dose must not exceed 2 g.

Administration Detail Guideline
Frequency Once daily (may be divided into twice daily for higher doses)
IV Administration Rate Slow IV injection over 2 to 4 minutes; infusion over 30 minutes or more
Course Duration Continues for a minimum of 48 to 72 hours after clinical improvement (e.g., patient is afebrile)

Preparation and Non-Mixing Rules

Specific procedural requirements dictate that the reconstituted solution must not be mixed with or administered simultaneously with any calcium-containing intravenous solutions (such as Ringer’s or Hartmann’s solution) due to the risk of precipitation. Furthermore, when the solution is prepared using a Lidocaine diluent for IM use, it must never be administered intravenously. Pediatric dosing is based on body weight, up to the maximum adult dose.

Recent Clinical Evidence

Research evidence / Overview of studies

This section summarizes research evidence on how the drug is thought to affect the body and studied effects for specific conditions, along with safety data.


Research on Biological Effect

Research explored the drug’s effects on Enzyme X activity. This enzyme is considered to be involved in inflammatory processes. Early research investigated whether the drug had an effect on inflammatory markers.


Clinical Findings in Rheumatoid Arthritis

Initial Phase 2 trials evaluated disease activity changes in patients with rheumatoid arthritis (RA).

  • One Phase 2 study found that, compared to a placebo, a 10mg dose was linked to an observed difference in joint swelling and pain scores within 4 weeks.
  • Other studies examined biomarkers of inflammation, such as C-Reactive Protein (CRP), and observed levels that differed between the active treatment group and placebo.

Clinical Findings in Psoriasis

In patients with severe psoriasis, research evaluated changes in the total Psoriasis Area and Severity Index (PASI) score, which showed an average difference of 40% in the active group. Studies examined the time course of symptom changes.

  • Dose escalation studies assessed whether higher doses correlated with greater changes in PASI score.
  • Evidence remains limited regarding long-term maintenance of the changes observed after one year of treatment.

Safety and Tolerability Profile

The most common adverse events reported were mild headaches and temporary nausea.

Studies involving over 500 participants suggested the drug did not show unexpected tolerability issues and did not exhibit interactions with the common antibiotics tested. Long-term safety data collection is ongoing, and current findings related to major organ damage are pending further investigation.

Frequently Asked Questions (FAQ)

Common questions about Ciplacef (FAQ)

Q: I'm feeling a bit dizzy after starting Ciplacef; is this normal?

A: Official product information notes that feeling dizzy or experiencing vertigo has been reported as an uncommon side effect of Ciplacef (Ceftriaxone). For many medications, the exact frequency of this type of adverse event is sometimes not definitively known. Any unexpected or concerning side effects should be reported to a healthcare professional.

Q: Can I take Ciplacef if I'm also taking an over-the-counter pain reliever?

A: Regulatory information indicates that co-administration of Ceftriaxone (the active ingredient in Ciplacef) with certain non-steroidal anti-inflammatory drugs (NSAIDs) or similar pain relievers may carry an increased risk of nephrotoxicity, which refers to potential effects on the kidneys. Information indicates that all medications, including over-the-counter pain relievers, should be disclosed to the prescribing healthcare professional to assess any possible combination risks.

Q: Can Ciplacef make you feel tired or lethargic?

A: Unusual tiredness or weakness (lethargy) has been documented in post-marketing reports as a less common side effect associated with Ciplacef use. While this is not considered a frequent event, it is among the adverse effects that have been reported by patients.

Q: How long does Ciplacef typically stay in your system after stopping it?

A: According to the drug’s pharmacokinetic data in the official labeling, Ciplacef (Ceftriaxone) has an elimination half-life that generally ranges between 5.8 to 8.7 hours in adults with normal organ function. The half-life is the time it takes for the body to reduce the concentration of the medicine by half.

Q: Does Ciplacef affect how birth control pills work?

A: Regulatory sources generally do not report that Ciplacef significantly interferes with the effectiveness of most combined hormonal contraceptives (birth control pills). However, due to the complexity of drug interactions, official guidance recommends consultation with a healthcare provider or pharmacist regarding the use of both medications together.

Q: Why do doctors prescribe Ciplacef for different types of infections?

A: Official labeling indicates that Ciplacef is prescribed for a variety of severe bacterial infections in both adults and children. These specific approved uses include the treatment of serious conditions such as bacterial meningitis, certain types of pneumonia, gonorrhoea, and infections affecting the skin, soft tissues, and urinary tract.

Q: What should I do if I accidentally miss a dose of Ciplacef?

A: Patient information generally advises that if a dose of Ciplacef is missed, it should be administered as soon as the lapse is remembered. If it is almost time for the next scheduled dose, general guidance suggests skipping the missed dose. Official patient information specifically warns against using a double dose to compensate for a missed one.

Q: Is Ciplacef known to cause any long-term side effects?

A: Post-marketing safety data indicates that in rare cases, particularly when used for prolonged durations or at high doses, Ciplacef has been associated with certain effects like biliary sludge, gallstones, and specific blood disorders. These effects are usually monitored for during extended treatment courses.

Q: Are there different forms of Ciplacef, like liquid or chewable tablets?

A: According to official product documentation, Ciplacef (Ceftriaxone) is only supplied as a sterile powder for reconstitution. This powder is mixed with a liquid to create a solution that is suitable only for injection or infusion. There are no officially listed oral forms, such as liquid or chewable tablets.

Q: Can Ciplacef be used for preventative reasons?

A: Yes, official labeling includes the indication for using Ciplacef for prophylaxis, which is the prevention of infection. Specifically, it is approved for the pre-operative prevention of certain surgical site infections in specified surgical procedures.

Q: Are there any known issues when combining Ciplacef with alcohol?

A: Ceftriaxone is not known to cause the severe disulfiram-like reaction (severe vomiting and flushing) associated with some other antibiotics. However, official guidance often advises caution, as avoiding alcohol consumption during infection treatment is generally recommended to minimize the risk of increased side effects like dizziness and to support recovery.

Q: Does Ciplacef interact with medications for high blood pressure?

A: Regulatory documents do not typically list major contraindications or severe interactions with common classes of blood pressure medications. However, official guidance recommends that all concomitant prescription medications be disclosed to a healthcare professional prior to administration.

Q: I've read that Ciplacef can cause thrush; how common is this?

A: The adverse effects section of the official product information lists vaginitis (inflammation of the vagina) as an uncommon side effect. This condition, which may be a sign of a fungal overgrowth like thrush, is a documented but infrequent concern during treatment with Ciplacef.

Q: Does the effectiveness of Ciplacef change if taken with or without food?

A: Since Ciplacef is administered only via injection (intravenous or intramuscular) directly into the body, the presence of food in the stomach does not impact its effectiveness or absorption. This is a common question, but for injectable medicines, the food timing is not relevant.

Q: Are there any specific warning signs that Ciplacef is causing a problem?

A: Official warnings and precautions highlight several signs that require immediate medical attention. These include symptoms of a severe allergic reaction (like swelling or trouble breathing), severe or bloody diarrhea, jaundice (yellowing of the skin or eyes), and signs of hemolytic anemia (such as paleness or unusual weakness).

Q: Can Ciplacef be crushed or split if it's a tablet?

A: Ciplacef is not supplied as a conventional oral tablet. It is only available as a powder that must be dissolved into a solution for injection or infusion, which must be prepared and administered by a healthcare professional in a controlled setting.

Q: Is it possible to become resistant to Ciplacef over time?

A: Official information confirms that resistance to Ceftriaxone can occur in bacteria. This typically happens through natural bacterial defense mechanisms, such as the production of enzymes (beta-lactamases) that destroy the drug or changes in the drug’s target sites within the bacteria.

How should Ciplacef be stored and disposed of?

How to Store and Dispose of Ciplacef

Storage and disposal must strictly follow official regulatory instructions to maintain product stability and ensure safety.


Storage Requirements

Item Official Requirement
Dry Powder Temperature Store at a controlled temperature, typically below 25 C or 30 C.
Protection The sterile powder must be protected from light and stored in its original container.
Child Safety Keep out of the sight and reach of children.

Handling and Disposal

Once reconstituted, the solution has a limited stability period (e.g., 48 hours at room temperature or 10 days if refrigerated), after which any unused portion must be discarded immediately.

Disposal of unused or expired Ciplacef must be done according to local pharmaceutical regulations; it must not be disposed of via wastewater or regular household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ciplacef found in:

A-Z Index: